Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives

Figures & data

Table 1 Patient Demographics and Baseline Characteristics (n=197)

Characteristics		Number	(%)
Age at diagnosis (years)	Median	42
	Range	19–74
Age group at diagnosis (years)	˂ 30	17	8.6
	30–39	68	34.5
	40–49	66	33.5
	50–59	38	19.3
	˃ 60	8	4.1
Nationality	Jordanian	170	86.3
	Others	27	13.7
Pathology	Invasive ductal carcinoma	171	86.8
	Other	26	13.2
Grade	I, II	42	21.3
	III	134	68.0
	NA	21	10.7
Stage	Early stage	184	93.4
	Metastatic	13	6.6

Table 2 BRCA1/2 Pathogenic Mutation Rates by Subgroups

Characteristics		Number of Patients	BRCA1/BRCA2 n (%)	P-value
Age at diagnosis (years)	<40	85	28 (32.9%)	0.034
	≥40	112	22 (19.6%)
Diagnosed at any age with two or more diagnoses of breast cancer at any age (synchronously or asynchronously)	Yes	29	12 (41.4)	0.032
	No	168	38 (22.6)
Diagnosed at age 50 years or younger with: 1 or more close relatives with breast cancer at any age, 1 or more close relatives with pancreatic cancer, or 1 or more close relatives with prostate cancer (Gleason score ≥7)	Yes	74	28 (37.8)	0.002
	No	123	22 (17.9)
Diagnosed at any age with 1 or more close relatives with breast cancer diagnosed at age 50 years or younger	Yes	47	19 (40.4)	0.007
	No	150	31 (20.7)
Nationality	Jordanian	170	41 (24.1)	0.307
	Others	27	9 (33.3)

Figure 1 Kaplan–Meier estimates of DFS: 81.6% in patients with positive BRCA1/2 mutation versus 86.7% in patients with no mutation, P=0.94.

Figure 2 Kaplan–Meier Estimates of OS: 92.5% in patients with positive BRCA1/2 mutation versus 92.0% in patients with no mutation, P=0.65.